

Clarification – MoU Recce Pharmaceuticals and PT Etana Biotechnologies

Sydney Australia, 13 February 2024: Recce Pharmaceuticals Limited (**ASX:RCE, FSE:R9Q**), ('Recce' or the '**Company**'), the company developing a New Class of Synthetic Anti-Infectives, wishes to clarify the announcement released 6 February 2024 surrounding the Memorandum of Understanding (**MoU**) between the Company and PT Etana Biotechnologies Indonesia ('**Etana**').

The purpose of the MoU is for both parties to work collaboratively on the research, development, production, distribution, and commercialisation of a first-in-class therapeutic agent designed with broad spectrum anti-infective capabilities for potential registrational use across Indonesia (and in other jurisdictions as otherwise agreed by the parties) to address the critical global health challenge of antimicrobial-resistance.

The Company has just returned from meetings in Jakarta with Etana, the Indonesian Health Ministry, the Indonesian Food and Drug Authority and the Indonesian National Research and Innovation Agency. The Company is currently in discussion with Indonesian parties to progress research and clinical projects and expects to enter into formal agreements within the present half year.

The Australian and Indonesia governments have each independently expressed a number of support initiatives to motivate the bilateral opportunity which the Company will provide an update on in due course. The Indonesian government has provided endorsement and access to hospitals for clinical trials, preclinical research facilities aimed at bringing new healthcare to Indonesia and the region.

The key terms contained in the MoU include:

- To support the expansion of Recce portfolio technology in the region, in research and commercialisation, support for clinical trials including navigating regulatory pathways and product registration.
- Co-operate to develop a research, development and commercialisation strategy to facilitate the Purpose.
- Facilitate the development of proposals in respect of the Projects, including the scope of work to be undertaken in connection for the Projects, timelines, roles and responsibilities of relevant Project Parties, objectives and resourcing.
- Determine the terms and conditions of the agreements under which the Projects will be conducted.
- Establish and conduct the Projects including to appoint the Project Parties.
- The MoU may be terminated by either party on 30 days prior written notice.

This announcement has been approved for release by Recce Pharmaceuticals Board.



ASX: RCE, FSE: R9Q

Head Office: Level 23, 180 George St, Salesforce Tower, SYDNEY NSW 2000 **T** +61 (02) 9256 2505

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA